SK bioscience, MSD, Hilleman Laboratories Partner to Enhance Ebola Vaccine

SK bioscience has announced a significant advancement in the development of a vaccine for Zaire ebolavirus through a new collaboration funded by the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative follows a funding agreement in which CEPI commits up to USD 30 million to MSD (Merck Sharp & Dohme), which will distribute the funds among its development partners, including SK bioscience and Hilleman Laboratories.

This collaboration aims to improve the existing Zaire ebolavirus vaccine, which is already prequalified by the World Health Organization (WHO). The focus will be on updating the complex manufacturing processes that currently require ultra-low temperature storage, a significant logistical challenge in remote areas where Ebola outbreaks frequently occur. By enhancing manufacturing yield and increasing the thermostability of the vaccine, the project seeks to make the vaccine more affordable and accessible, particularly for low- and middle-income countries.

Collaboration Details and Goals

Hilleman Laboratories, a joint venture between MSD and the Wellcome Trust, will spearhead the clinical development of the updated vaccine. Meanwhile, SK bioscience, in partnership with IDT Biologika, will work on refining the drug substance manufacturing process and the associated drug product. This collaboration positions SK bioscience as a key player in improving vaccine production capabilities, leveraging its expertise and infrastructure to contribute to global health preparedness.

The Zaire ebolavirus is notorious for causing unpredictable outbreaks, with a survival rate of approximately 50%. Recent incidents in the Democratic Republic of the Congo have highlighted the ongoing global threat posed by this virus, especially in regions lacking adequate healthcare frameworks.

Dr. Richard Hatchett, CEO of CEPI, emphasized the importance of this initiative, stating, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks. CEPI’s support will help enable a sustainable and accessible supply of MSD’s Zaire ebolavirus vaccine for years to come at a more affordable price.”

Jaeyong Ahn, CEO of SK bioscience, echoed this sentiment, asserting that tackling deadly infectious diseases like Ebola requires robust global collaboration. He noted, “Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire ebolavirus vaccine manufacturing and supply, contributing meaningfully to global health preparedness.”

Commitment to Global Health

SK bioscience has a proven track record of collaborating with international health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By harnessing its comprehensive capabilities in vaccine development, manufacturing, and supply, the company is poised to expand its impact in public health-driven vaccine initiatives globally.

As the world faces the continuing challenge of infectious diseases, the collaboration between SK bioscience, MSD, and Hilleman Laboratories represents a proactive step towards ensuring that vaccines are not only effective but also accessible to those who need them most. With a commitment to improving public health solutions, SK bioscience is dedicated to leveraging cutting-edge technologies to promote human health worldwide.